Program
CKD-378
A development code. Also written as “CKD-378 25/1000mg”, “CKD-378, QD, PO” and “CKD-378, QD, PO Drug: D745, D150, QD, PO”.
Its studies are mostly in Diabetes Mellitus, Type 2, led by Chong Kun Dang Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chong Kun Dang Pharmaceutical | 40 open or running | phase 1since Feb 14, 2023 | Feb 14, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 14, 2023First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT05741437 · 24 enrolled · Korea, Republic of
- May 18, 2023Phase 1 study in Diabetes Mellitus, Type 2NCT05881213 · 23 enrolled · Korea, Republic of
- Apr 23, 2024Phase 1 study in Diabetes Mellitus, Type 2NCT06386328 · 31 enrolled · South Korea
- Nov 26, 2024Phase 1 study in Diabetes Mellitus, Type 2NCT06709807 · 31 enrolled · Korea, Republic of
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06709807Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | Completed | Dec 7, 2024 | 31 |
| NCT06386328Diabetes Mellitus, Type 2 · South Korea | 1 | Completed | Jun 3, 2024 | 31 |
| NCT05881213Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | Completed | Jun 28, 2023 | 23 |
| NCT05741437Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | Completed | Aug 31, 2023 | 24 |
How it is read
Names in the registry
- “CKD-378 25/1000mg”, 1 entry
- “CKD-378, QD, PO”, 1 entry
- “CKD-378, QD, PO Drug: D745, D150, QD, PO”, 1 entry
- “CKD-378 (low-dose)”, 1 entry
Codes read as this program: CKD378.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.